DAN-troe-leen
REMS
Absorption: 35% absorbed after oral administration. IV administration results in complete bioavailability.
Distribution: Widely distributed to tissues.
Half-Life: 8.7–11.4 hr.
Contraindicated in:
Use Cautiously in:
Women and patients >35 yr (↑ risk of hepatotoxicity);
Use lowest possible dose in older adults (↑ risk of hepatotoxicity)
.CV: changes in BP, HF, tachycardia
Derm: flushing, pruritus, sweating, urticaria
EENT: excessive lacrimation, visual disturbances
GI: diarrhea, anorexia, cramps, dysphagia, GI bleeding, HEPATOTOXICITY, nausea, vomiting
GU: crystalluria, dysuria, erectile dysfunction, frequency, incontinence, nocturia
Hemat: anemia, aplastic anemia, eosinophilia, leukopenia, thrombocytopenia
Local: irritation at IV site, phlebitis
MS: myalgia
Neuro: drowsiness, muscle weakness, confusion, dizziness, headache, insomnia, malaise, nervousness
Resp: dyspnea, pleural effusion, respiratory depression
Misc: ANAPHYLAXIS, chills, drooling, fever
Drug-drug:
Drug-Natural Products:
Because of the potential risk of hepatotoxicity with long-term use, dantrolene therapy should be discontinued if benefits are not evident within 45 days.
Spasticity
Prevention of Malignant Hyperthermia
Treatment of Malignant Hyperthermia
Neuroleptic Malignant Syndrome (unlabeled)
Lab Test Considerations:
Monitor liver function at baseline and frequently during therapy. Liver function abnormalities (↑ AST, ALT, alkaline phosphatase, bilirubin, GGT) may require discontinuation of therapy.
IV Administration:
Treatment of Malignant Hyperthermia
Prevention of Malignant Hyperthermia
NDC Code